Clinical Trials

HCA Midwest Health currently has 12 clinical cancer trials available. Our clinical research program looks at new ways to prevent, detect, or treat disease.

Important Information


CDC guidance now recommends that moderately to severely immunocompromised patients receive an additional (third) dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). If you have undergone anti-cancer therapy in the past year, you are within 1 year of stem cell transplantation or are receiving medications that suppress your immune system, you are encouraged to obtain a third COVID-19 vaccination shot. If you received the Johnson & Johnson single dose vaccination, please consult your doctor regarding next steps. Find vaccination locations here.

If you are within 100 days of a stem cell transplantation, we do not recommend that you receive a COVID-19 vaccination until you are cleared by your care team to do so. If you are currently on a clinical research trial, please contact your clinical research team for more guidance. Please contact your care coordinator if you have additional questions about receiving an additional COVID-19 vaccine shot.

The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through Sarah Cannon Research Institute and various pharmaceutical and CRO partners.

AML 40: A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center

AML 52: Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine VS Venetoclax _ Aza in Newly Diagnosed AML Unfit for Intensive Chemo. PI: Suman Kambhampati, MD
Facility: Research Medical Center

LYM 120: Phase 2b Study of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Previously Treated DLBCL. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Research Medical Center, Menorah Medical Center

LYM 155: Phase 2 Study of Acalabrutinib as Post-AutoSCT Maintenance Therapy in Subjects with MCL. PI: Suman Kambhampati, MD.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 169: Phase 3 study of brentuximab vedotin/placebo + lenalidomide in R/R DLBCL. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

LYM 172: Phase 3, Study of R-CHOP Alone vs R-CHOP + Acalabrutinib as FL in Subjects ≤65 Years with Non-Germinal Center DLBCL, PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MDS 26: Study of Magrolimab + Azacitidine vs Azacitidine + Placebo in Treatment-naïve Patients with Higher Risk MDS, PI: Suman Kambhampati, MD
Facility: Research Medical Center

MDS 27: Phase 3 Study of Venetoclax + Aza in Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS). PI: Suman Kambhampati, MD
Facility: Research Medical Center

MM 109: Study of Dara + Len vs. Lenalidomide Alone as Maint. in newly diagnosed Multiple Myeloma Who Are MRD + after Frontline AutoSCT. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MM 123: Phase 3 Study of GSK2857916 + Pom. and Low-Dose Dex. vs Pom. + Bortezomib and Low Dose Dexa in R/R MM (DREAMM 8). PI: Suman Kambhampati, MD
Facility: Research Medical Center

MPN 11: Phase 3 Study of Navitoclax w/wo Ruxolitinib in Myelofibrosis and no prior treatment with JAK-2 inhibitor therapy (Transform-1)
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

MPN 12: Phase 2 open-label study evaluating tolerability and efficacy of Navitoclax alone or in combination with ruxolitinib in subjects with myelofibrosis, PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center

Amaze – SentreHeart: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Amulet – Abbott: Study to determine if Amulet device is safe and effective when compared to Watchman device. Randomized 1:1 Watchman vs Amulet. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

ASAP Too – Boston Scientific: Evaluate the safety and effectiveness of the Lariat Suture Delivery system to percutaneously isolate and ligate the LAA from the LA as an adjunct to a planned PVI catheter ablation in persistent or longstanding persistent. PI: Dr. Yoaav Krauthammer
Facility: Overland Park Regional Medical Center, Research Medical Center

Catalyst – Abbott: The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center

Diamond AF II – Epix: Evaluate the safety and effectiveness of the Diamond tipped catheter ablation system. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Node 301 – Milestone: Determine whether etripamil nasal spray 70 mg self-administered by patients is superior to placebo at terminating episodes of PSVT in an outpatient setting. This is a study that involves the patient coming back for a 2 hour Research visit at OPR. PI: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center

Xe-POHCAS – Neuroprote Xeon Inc.: Evaluation on Days 30 and 90 post OHCA, whether there is a difference in functional outcome in comatose subjects who achieved ROSC within 30 minutes after OHCA and were treated with xenon 50% plus oxygen vs standard of care treatment without xenon during TTM. PI:Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center